{"id":"https://openalex.org/W4312216632","doi":"https://doi.org/10.36316/gcatr.04.0045","title":"Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments","display_name":"Pharmacovigilance Principles: The Building Blocks of Benefit-Risk Assessments","publication_year":2022,"publication_date":"2022-11-03","ids":{"openalex":"https://openalex.org/W4312216632","doi":"https://doi.org/10.36316/gcatr.04.0045"},"language":"en","primary_location":{"id":"doi:10.36316/gcatr.04.0045","doi":"https://doi.org/10.36316/gcatr.04.0045","is_oa":false,"landing_page_url":"https://doi.org/10.36316/gcatr.04.0045","pdf_url":null,"source":{"id":"https://openalex.org/S4210232897","display_name":"Global Clinical and Translational Research","issn_l":"2641-7154","issn":["2641-7154","2643-8151"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Global Clinical and Translational Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072822505","display_name":"Rosa Piccirillo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rosa Piccirillo","raw_affiliation_strings":["iQVIA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"iQVIA","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"last","author":{"id":null,"display_name":"Jennifer Parish","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jennifer Parish","raw_affiliation_strings":["IQVIA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA","institution_ids":["https://openalex.org/I28927889"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I28927889"],"apc_list":null,"apc_paid":null,"fwci":0.5136,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.59339325,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":null,"issue":null,"first_page":"1","last_page":"7"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.9580000042915344},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.656000018119812},{"id":"https://openalex.org/keywords/regulatory-guidance","display_name":"regulatory guidelines","score":0.6420000195503235},{"id":"https://openalex.org/keywords/qualitative-risk-analysis","display_name":"qualitative risk analysis","score":0.7369999885559082},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6729999780654907},{"id":"https://openalex.org/keywords/drug-life-cycle","display_name":"drug life cycle","score":0.39500001072883606},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5370000004768372}],"concepts":[{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7855076789855957},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.687192440032959},{"id":"https://openalex.org/C108759981","wikidata":"https://www.wikidata.org/wiki/Q788590","display_name":"Authorization","level":2,"score":0.6565156579017639},{"id":"https://openalex.org/C90673727","wikidata":"https://www.wikidata.org/wiki/Q901718","display_name":"Product (mathematics)","level":2,"score":0.6073704957962036},{"id":"https://openalex.org/C12174686","wikidata":"https://www.wikidata.org/wiki/Q1058438","display_name":"Risk assessment","level":2,"score":0.5756269097328186},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5671641826629639},{"id":"https://openalex.org/C2777589142","wikidata":"https://www.wikidata.org/wiki/Q6770899","display_name":"Marketing authorization","level":2,"score":0.46456706523895264},{"id":"https://openalex.org/C26517878","wikidata":"https://www.wikidata.org/wiki/Q228039","display_name":"Key (lock)","level":2,"score":0.4509890675544739},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.2600063383579254},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2281939685344696},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.15848711133003235},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.13298293948173523},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.07120615243911743},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.36316/gcatr.04.0045","doi":"https://doi.org/10.36316/gcatr.04.0045","is_oa":false,"landing_page_url":"https://doi.org/10.36316/gcatr.04.0045","pdf_url":null,"source":{"id":"https://openalex.org/S4210232897","display_name":"Global Clinical and Translational Research","issn_l":"2641-7154","issn":["2641-7154","2643-8151"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Global Clinical and Translational Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.504800021648407}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W197563957","https://openalex.org/W1868158647","https://openalex.org/W2023678134","https://openalex.org/W2055903002","https://openalex.org/W2130923633","https://openalex.org/W2201685611","https://openalex.org/W2898257638","https://openalex.org/W3016416120","https://openalex.org/W3028772421","https://openalex.org/W4236145897","https://openalex.org/W4241252796","https://openalex.org/W4244872385","https://openalex.org/W4294718684","https://openalex.org/W6776598222"],"related_works":["https://openalex.org/W4312216633","https://openalex.org/W2270517737","https://openalex.org/W7097044966","https://openalex.org/W2898257638","https://openalex.org/W3111995644","https://openalex.org/W2601077192","https://openalex.org/W2989449104","https://openalex.org/W2501216116","https://openalex.org/W183272536","https://openalex.org/W4318755522"],"abstract_inverted_index":{"A":[0],"medicinal":[1,43],"product":[2],"must":[3],"demonstrate":[4],"a":[5,42,49,70,92],"favorable":[6],"benefit-risk":[7,29,71,94],"balance":[8],"to":[9,27,47,60,76,88],"remain":[10],"on":[11,34,63],"the":[12,15,20,39,64,81,89],"market.":[13],"That":[14],"benefits":[16],"of":[17,41,69,80,91],"use":[18],"outweigh":[19],"risks":[21],"is":[22],"established":[23],"using":[24],"analyses":[25],"referred":[26],"as":[28],"assessments,":[30],"which":[31],"are":[32],"conducted":[33],"an":[35,78],"ongoing":[36],"basis":[37],"throughout":[38],"lifecycle":[40],"product.":[44],"While":[45],"fundamental":[46],"maintaining":[48],"product\u2019s":[50],"marketing":[51],"authorization,":[52],"few":[53],"regulatory":[54],"guidance":[55],"documents":[56],"have":[57],"been":[58],"developed":[59],"provide":[61,77],"information":[62],"specific":[65],"content":[66],"and":[67],"structure":[68],"assessment.":[72],"This":[73],"paper":[74],"aims":[75],"overview":[79],"key":[82],"concepts":[83],"in":[84],"pharmacovigilance":[85],"that":[86],"contribute":[87],"creation":[90],"structured":[93],"assessment,":[95],"particularly":[96],"through":[97],"qualitative":[98],"analysis.":[99]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-01-04T00:00:00"}